Demyelinating Autoimmune Diseases, CNS
14
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.4% vs benchmark
14%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (14)
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
Aerobic Exercise for Remyelination in Multiple Sclerosis
Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study
Power Training in Older Multiple Sclerosis Patients
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
A Registered Cohort Study of Inflammatory Demyelination Disease
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome
Autologous Stem/Stromal Cells in Neurological Disorders and Disease
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis